Celularity Inc
CELUW0.050USD
-0.000-0.20%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Celularity Inc Unternehmen
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
Unternehmensinformationen
BörsenkürzelCELUW
Name des UnternehmensCelularity Inc
IPO-datumMay 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
Anzahl der mitarbeiter- -
WertpapierartCompany Warrant
Geschäftsjahresende- -
Addresse170 Park Ave
StadtFLORHAM PARK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl07932
Telefon19087682170
Websitehttps://celularity.com/
BörsenkürzelCELUW
IPO-datumMay 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Vincent Levien
Mr. Vincent Levien
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 2
Aktualisiert: Wed, Jul 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Other
100.00%
Aktionäre
Aktionäre
Anteil
Other
100.00%
Aktionärstypen
Aktionäre
Anteil
Other
100.00%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
27
2.48M
0.00%
-1.91M
2025Q1
31
2.48M
0.00%
-2.12M
2024Q4
30
2.60M
0.00%
-2.17M
2024Q3
31
2.80M
0.00%
-1.78M
2024Q2
32
2.67M
0.00%
-2.18M
2024Q1
32
2.68M
0.00%
-2.18M
2023Q4
31
3.99M
0.00%
-892.77K
2023Q3
31
4.57M
0.00%
-1.21M
2023Q2
29
5.51M
0.00%
-1.17M
2023Q1
26
6.63M
0.00%
-928.95K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Walleye Capital LLC
850.11K
0%
-86.66K
-9.25%
Mar 31, 2025
Linden Advisors L.P.
550.12K
0%
--
--
Mar 31, 2025
Healthcare Of Ontario Pension Plan
350.00K
0%
--
--
Mar 31, 2025
Peak6 Capital Management LLC
171.36K
0%
--
--
Mar 31, 2025
Davidson Kempner Capital Management LP
150.80K
0%
--
--
Mar 31, 2025
Context Capital Management LLC
150.00K
0%
--
--
Mar 31, 2025
Shay Capital LLC
99.07K
0%
-47.76K
-32.53%
Mar 31, 2025
Corient Private Wealth LLC
55.00K
0%
--
--
Mar 31, 2025
EMFO, LLC
50.00K
0%
--
--
Jun 30, 2024
Clear Street LLC
11.91K
0%
-200.00
-1.65%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
